ClinicalTrials.gg
Active, not recruitingNCT04829604Updated Mar 9, 2026

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

A Phase 2 interventional study of ARX788 in HER2 Positive Metastatic Breast Cancer, sponsored by Ambrx, Inc.. Active, not recruiting at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Ambrx, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ARX788 in Breast Neoplasms — 3 open to participants now, 5 under way, 1 of them phase 3. ARX788 · Breast Neoplasms.

Enrollment
4th of 10
72 · median 49
Started
2021
with 3 others
Phase 2
7 of 10
3 open now
Registered
4th of 10
by date
Lead sponsor
3 of 10
Ambrx, Inc.

Among the 10 studies testing ARX788 in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 2, and was the 4th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 10 studies testing ARX788 in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ARX788

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ARX788 in Breast Neoplasms, or all of them as a file.
02

Study summary

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd

Read the detailed description

A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.

03

Conditions studied

  • HER2 Positive Metastatic Breast Cancer

Keywords

  • HER2-postive
  • Breast cancer
  • Antibody drug
  • Metastatic
  • ARX788
  • HER2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥ 18 years and older
  • ≥ 6 months
  • Unresectable or breast cancer subjects
  • Presence of at least one per v 1.1
  • Subjects must have positive breast cancer per ASCO-CAP guidelines, documented in a CLIA lab pathology report
  • Subjects must have had prior treatment with no more than 5 prior regimens of systemic treatment HER-2 targeting therapy or chemotherapy in the metastatic setting. One of these prior treatments must have been treatment with T-DXd.
  • Subjects with stable
  • Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1 as per the v 5.0, except alopecia, vitiligo, Grade 2 peripheral neuropathy, or endocrine toxicities that are stable on hormone replacement.
  • Adequate organ functions
  • Willing and able to understand and sign an inform and to comply with all aspects of the protocol

Key Exclusion Criteria:

Any subject who meets any of the following criteria is excluded from the study:

  • History of allergic reactions to any component of ARX788.
  • Prior history of interstitial lung disease, pneumonitis, or other lung disease. Any requirement for supplemental oxygen.
  • Any active ocular infections or chronic corneal disorders
  • History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, cardiac arrhythmia, or myocardial infarction within 6 months prior to enrollment
  • Grade 3 to 4 peripheral neuropathy (NCI CTCAE v 5.0).
  • History of unstable central nervous system (CNS) metastases
  • Radiotherapy outside of the brain administered \< 7 days prior to first dose of ARX788
  • Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic diseases)
  • Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments
  • Exposure to any other or commercial anticancer agents or therapies administered with the intention to treat within 14 days before the first dose of ARX788
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    ARX788

    The investigational medicinal product (IMP), ARX788, will be administered every 3 weeks (Q3W) by intravenous (IV) infusion.

    Drug: ARX788

Interventions

  • DrugARX788

    The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269

    Also known as: antibody drug conjugate (ADC)

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    To evaluate the confirmed objective response rate (ORR) as determined by Investigator assessment based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) following treatment with ARX788. The ORR is defined as the number of subjects with a BOR of CR or PR divided by the number of response evaluable subjects.

    Time frame: 2 years

Secondary outcomes

  1. Duration of response (DOR)

    DOR is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first, will be computed for subjects with a BOR of CR or PR.

    Time frame: 2 years

  2. Best overall response (BOR)

    BOR is defined as the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started)

    Time frame: 2 years

  3. Disease control rate (DCR)

    DCR is defined as the proportion of complete response (CR), partial response (PR), and stable disease (SD) rates.

    Time frame: 2 years

  4. Overall survival (OS)

    Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive.

    Time frame: 2.5 years

  5. Progression-free survival (PFS)

    PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy

    Time frame: 2 years

  6. The number of subjects experiencing adverse event TEAEs

    Patient safety and adverse events (AEs) will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. All AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the treatment.

    Time frame: 2 years

  7. Maximum serum concentration (Cmax) for ARX788

    Pharmacokinetic parameter maximum serum concentration (Cmax) for ARX788, ADC, ADA, total antibody, and pAF-AS269

    Time frame: Cycle 1 and cycle 3

  8. Trough concentration (Ctrough) for ARX788

    Pharmacokinetic parameter trough concentration (Ctrough) for ARX788, ADC, total antibody, and pAF-AS269

    Time frame: Cycle 1 and cycle 3

  9. Area under the serum concentration-time curve (AUC) for ARX788

    Pharmacokinetic parameter area under the serum concentration-time curve (AUC) for ARX788, ADC, total antibody, and pAF-AS269

    Time frame: Cycle 1 and cycle 3

  10. Time to response (TTR)

    Time it takes for patient to respond to study treatment

    Time frame: Start of treatment to first objective confirmed BOR of CR or PR, assessed for approximately 2 years

Other outcomes

  1. Evaluate Biomarker

    To evaluate exploratory blood- and tissue-based biomarkers related to study drug response

    Time frame: 2 years

07

Study locations

33 sites
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    San Francisco, California 94158, United States
  • Research Site
    Whittier, California 90602, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    Silver Spring, Maryland 20904, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Camden, New Jersey 08103, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10028, United States
  • Research Site
    Shirley, New York 11967, United States
  • Research Site
    The Bronx, New York 10469, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Tigard, Oregon 97223, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Frankston, Victoria 3199, Australia
  • Research Site
    Geelong, Victoria 3220, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Daegu, 42601, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 02841, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 62 months is above that.

Counting every sponsor, half of 1,303 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Apr 2, 2021
StartActual
Oct 26, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04829604
Lead sponsor
Ambrx, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Oct 26, 2021
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 9, 2026

Study contacts

Ambrx
study director · Ambrx, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARX788

Start the discussion